Article Versions Notes

Upadhyay SK, Verone A, Shoemaker S, Qin M, Liu S, Campbell M, Hershberger PA. 1,25-Dihydroxyvitamin D₃ (1,25(OH)₂D₃) Signaling Capacity and the Epithelial-Mesenchymal Transition in Non-Small Cell Lung Cancer (NSCLC): Implications for Use of 1,25(OH)₂D₃ in NSCLC Treatment. Cancers. 2013; 5(4):1504-1521. https://doi.org/10.3390/cancers5041504

Upadhyay, Santosh Kumar, Alissa Verone, Suzanne Shoemaker, Maochun Qin, Song Liu, Moray Campbell, and Pamela A. Hershberger. 2013. "1,25-Dihydroxyvitamin D₃ (1,25(OH)₂D₃) Signaling Capacity and the Epithelial-Mesenchymal Transition in Non-Small Cell Lung Cancer (NSCLC): Implications for Use of 1,25(OH)₂D₃ in NSCLC Treatment" Cancers 5, no. 4: 1504-1521. https://doi.org/10.3390/cancers5041504

Upadhyay, S. K., Verone, A., Shoemaker, S., Qin, M., Liu, S., Campbell, M., & Hershberger, P. A. (2013). 1,25-Dihydroxyvitamin D₃ (1,25(OH)₂D₃) Signaling Capacity and the Epithelial-Mesenchymal Transition in Non-Small Cell Lung Cancer (NSCLC): Implications for Use of 1,25(OH)₂D₃ in NSCLC Treatment. Cancers, 5(4), 1504-1521. https://doi.org/10.3390/cancers5041504